Double autologous stem cell transplantation for multiple myeloma: a Korean single center study.
BACKGROUND
Although high dose chemotherapy coupled with an autologous stem cell transplantation (ASCT) is widely accepted as effective therapy for multiple myeloma (MM), few reports are available in Korea, especially in the area of double ASCT. We present the results of an institutional retrospective study of 12 patients with MM treated by double ASCT.


METHODS
Eligible patients received induction therapy using vincristine, adriamycin, dexamethasone (VAD), and mobilization was performed using cyclophosphamide plus lenograstim. High-dose melphalan (total 200 mg/m2) was used to condition the ASCT.


RESULTS
The median interval from diagnosis to ASCT was 6 months (range, 1.8-15.3 months). The median interval between the 1st and 2nd ASCT was 4.4 months (range 2.1-48.7 months). The median follow up was 18.3 months (range 8.1-50.5 months) for the nine surviving patients. No therapy-related mortality occurred. Following induction chemotherapy, two patients experienced CR. Following double ASCT, eight patients experienced CR. The 5 year OS was 59%. The median duration of event free survival was 2.13 years (95% CI, 0.84-3.42).


CONCLUSIONS
Although the results of study did not demonstrate the advantage of double ASCT, this is the first report to outline the outcome of double ASCT for Korean MM patients.
Ko
Ock Bae
OB
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Kim
Shin
S
Shim
Hyeok
H
Lee
Jung-Hun
JH
Ahn
Jung-Min
JM
Yoon
Soon-Man
SM
Jeon
Min-Hyok
MH
Do
Il-No
IN
Lee
So-young
SY
Kim
Yong Gil
YG
Kim
Sang We
SW
Kim
Sung-Bae
SB
Kim
Sang-Hee
SH
Lee
Jung Shin
JS
Kim
Wookun
W
Park
Chan-Jung
CJ
Chi
Hyun-sook
HS
Suh
Cheolwon
C
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007723:Korea; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D000078224:Lenograstim; D003907:Dexamethasone; D004317:Doxorubicin